MT Newswires Live01-09
Abivax (ABVX) said Thursday that it reached 82% of target enrollment in a phase 3 trial evaluating obefazimod for the treatment of moderately to severely active ulcerative colitis.
Enrollment stood at 1,003 of 1,224 targeted participants and is expected to be completed in Q2, according to the biotechnology company.
The company's cash runway will extend beyond the trial readout and into Q4, Abivax said.
Price: 6.68, Change: -0.30, Percent Change: -4.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Vermilion Energy Inc : JP Morgan Cuts Target Price to C$11 From C$10
Astral Asia Bhd - March Palm Kernel Productions 71 M/T
Iconic Worldwide - Under Judgement, Court Dismissed Lfsb's Claim of 15 Mln RGT in Total, Others
Iconic Worldwide - on April 22, High Court of Malaya, Penang Delivered Judgement in Favour of Defendant, Iconic Medicare
Sap Se : Bofa Global Research Raises Price Objective to EUR 303 From EUR 302